Published Scientific Articles
Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells
Brk/Protein tyrosine kinase 6 phosphorylates p27KIP1, regulating the activity of cyclin D-cyclin-dependent kinase 4
Tyrosine phosphorylation of the p21 cyclin-dependent kinase inhibitor facilitates the development of proneural glioma
Inflammatory Mediators of Esophagitis Alter p27Kip1 Expression in Esophageal Epithelial Cells
Concarlo in the News
Concarlo Therapeutics Presents Novel Therapeutic Approach for ER+ Metastatic Breast Cancer Targeting the CDK Pathway
Many startups are built off research, so why don’t more scientists become founders?
CDK Inhibitors: Why Women – and Men – Should Know About This ‘New Era’ Of Cancer Treatment
Breast Cancer Deserves More Than A Month
Webinars & Talks
The academic to founder pipeline with Dr. Stacy Blain from Concarlo Therapeutics
LabOps: Changing Outcomes for Drug-Resistant Patients with Stacy Blain, Founder, and CSO at Concarlo Therapeutics
Case Study: Developing liposomal formulation of a novel 91-mer synthetic peptide for treatment of ER+ CDK4i resistant Breast Cancer
The Cancer Moonshot: A 5 Year Review
Awards
“The reward for work well done is the opportunity to do more”
—Jonas Salk
RESI’s Innovator’s Pitch Challenge Winner
Princeton University Women’s Showcase
The 50 Most admired companies: CIO Bio
Top 100 entreprenuers: Alumni List
Top Biotech Startup 2022
Awarded by: Life Sciences Review
